Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain

• Status: Completed
• Trial end date: 2018-05-02
• Target enrollment: 0
• Participant gender: All

Summary

A Randomized, Double-blind, Active-Controlled, Multi-center, Phase 3 Trial to Compare the Safety and Efficacy between YHD1119 and Pregabalin in Patients with Peripheral Neuropathic Pain

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yuhan Corporation
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Signed Informed Consent

• HbA1c ≤ 9.5% diabetes mellitus patients with pain over 6 months in Diabetic Peripheral Neuropathy or postherpetic Neuralgia patients at least 3 months pain after diagnosis of skin rash due to herpes zooster

Exclusion Criteria:

• Have Brittle diabetes mellitus